/
Other
Single Ascending Dose
13
Pipeline Programs↗
16
Active Trials↗
94
Companies Involved↗
Single Ascending Dose is an emerging landscape with 13 programs across 94 companies. The most active players are Metro International Biotech, LLC, Beijing Suncadia Pharmaceuticals Co., Ltd, Design Therapeutics, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
MPhase 1BPhase 1DPhase 1APhase 1CPhase 1
Phase 1
Metro International Biotech, LLC
1 program
Beijing Suncadia Pharmaceuticals Co., Ltd
1 program
Design Therapeutics, Inc.
1 program
Antidote Therapeutics, Inc
1 program
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
1 program
Hanmi Pharmaceutical Company Limited
1 program
Pipeline
Programs by Phase
Preclinical1
Phase 112
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
238
clinical trials
Completed197 · 83%
Terminated14 · 6%
Recruiting8 · 3%
Not yet recruiting7 · 3%
Unknown status7 · 3%
Withdrawn4 · 2%
Other1 · 0%
Clinical Trials
Trial Activity
238 trials
First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection
Not yet recruiting·SSynphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.·Phase 1·NCT07334249·80 enrolled
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061
Not yet recruiting·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 1·NCT07241910·40 enrolled
Page 1 of 16
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)